Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

10

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial penicillin-binding protein

6

Canalicular multispecific organic anion transporter 1

3

Myeloperoxidase

3

Oligopeptide transporter small intestine isoform

3

Solute carrier family 15 member 2

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

12

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1954

1

1958

1

1979

3

1991

2

1997

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Pharyngitis

6

Tonsillitis

6

Acute exacerbations of chronic bronchitis

3

Acute maxillary sinusitis

3

Community-acquired pneumonia

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

7

Primary

5

Preventing

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

5

CNS Non-penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Eli Lilly

3

Fujisawa Pharmaceutical

3

KAI Pharmaceuticals

2

Sanofi-Aventis

2

Pfizer

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

12

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

12

FDA UNII

12

PUBCHEM

12

EPA CompTox

10

DRUG BANK

9

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

3

ALIMENTARY TRACT AND METABOLISM

1

CARDIOVASCULAR SYSTEM

1

SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

3

AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM

1

CALCIUM HOMEOSTASIS

1

DRUGS USED IN DIABETES

1

LIPID MODIFYING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER BETA-LACTAM ANTIBACTERIALS

3

ACE INHIBITORS, COMBINATIONS

1

ACE INHIBITORS, PLAIN

1

ANTI-PARATHYROID AGENTS

1

BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Second-generation cephalosporins

2

ACE inhibitors and calcium channel blockers

1

ACE inhibitors and diuretics

1

ACE inhibitors, other combinations

1

ACE inhibitors, plain

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

6

Salts, Hydrates, Esters, etc.

6

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 11 - 12 of 12 results

First page
Previous page
2
Next page disabled
Next page disabled

CEFACLOR DIHYDRATE

M96BT853SD

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First approved in 1979

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Oligopeptide transporter small intestine isoform

Solute carrier family 15 member 2

Canalicular multispecific organic anion transporter 1

Bacterial penicillin-binding protein

Conditions:

Lower respiratory tract infections

Skin and skin structure infections

Urinary tract infections

Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following in...

fections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.

CEFACLOR

69K7K19H4L

Export Data
Search for Structure

Status:

US Approved Rx (2002)

First approved in 1979

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Oligopeptide transporter small intestine isoform

Solute carrier family 15 member 2

Canalicular multispecific organic anion transporter 1

Bacterial penicillin-binding protein

Conditions:

Lower respiratory tract infections

Skin and skin structure infections

Urinary tract infections

Cefaclor is a semisynthetic cephalosporin antibiotic for oral administration. As with other cephalosporins, the bactericidal action of Cefaclor results from inhibition of cell-wall synthesis. Cefaclor is indicated in the treatment of the following in...

fections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes; Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes; Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes; Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci; Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes. Adverse effects considered to be related to therapy with cefaclor are: Hypersensitivity reactions, Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, somnolence and diarrhea. Patients receiving Cefaclor may show a false-positive reaction for glucose in the urine with tests that use Benedict's and Fehling's solutions and also with Clinitest® tablets. There have been reports of increased anticoagulant effect when Cefaclor and oral anticoagulants were administered concomitantly.

Showing 11 - 12 of 12 results

First page
Previous page
2
Next page disabled
Next page disabled

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1